A carregar...
Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia
We aim to report a CML case that had fluid retention and serum creatinine increase under long-term imatinib mesylate (IM) treatment. A 68-year-old woman was diagnosed with chronic myeloid leukemia, and IM was started in 2002 with a dose of 400 mg/day. She had achieved complete hematological, molecul...
Na minha lista:
| Publicado no: | Open Med (Wars) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
De Gruyter
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6310919/ https://ncbi.nlm.nih.gov/pubmed/30613793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1515/med-2019-0004 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|